Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in CHF (TTM)41.35bn
- Net income in CHF8.53bn
- Incorporated1996
- Employees76.06k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| IFM Due Inc | 12.54% | 835.00m |
| Cytokinetics Inc | 9.03% | -- |
| Calypso Biotech BV | 9.03% | 425.00m |
| SanReno Therapeutics | 9.72% | -- |
Data delayed at least 15 minutes, as of Sep 19 2024 16:03 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi SA | 44.60bn | 3.97bn | 122.91bn | 87.99k | 30.61 | 1.77 | 20.04 | 2.76 | 3.36 | 3.36 | 37.84 | 58.10 | 0.3716 | 1.43 | 5.64 | 538,639.00 | 3.39 | 5.87 | 4.33 | 7.16 | 68.91 | 68.78 | 9.11 | 16.90 | 0.6484 | 34.81 | 0.2454 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Pfizer Inc | 47.09bn | -2.19bn | 142.66bn | 88.00k | -- | 1.92 | 40.78 | 3.03 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 26.18bn | 2.65bn | 151.38bn | 26.70k | 57.31 | 30.18 | 21.80 | 5.78 | 5.81 | 5.81 | 57.47 | 11.03 | 0.3415 | 1.75 | 4.85 | 1,158,577.00 | 3.46 | 10.36 | 4.39 | 13.06 | 63.30 | 75.41 | 10.12 | 26.51 | 0.8928 | 1.59 | 0.9136 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| AstraZeneca plc | 41.58bn | 5.45bn | 205.52bn | 89.90k | 37.97 | 6.15 | 21.00 | 4.94 | 3.12 | 3.12 | 23.81 | 19.29 | 0.4892 | 1.63 | 4.44 | 413,662.70 | 6.42 | 3.34 | 8.84 | 4.61 | 82.21 | 79.64 | 13.12 | 7.69 | 0.6905 | 7.91 | 0.4585 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novartis AG | 41.35bn | 8.53bn | 214.70bn | 76.06k | 23.67 | 5.62 | 14.84 | 5.19 | 4.14 | 6.63 | 20.04 | 17.44 | 0.4687 | 1.77 | 5.61 | 543,609.80 | 9.67 | 8.53 | 13.56 | 11.23 | 74.75 | 72.93 | 20.64 | 22.68 | 0.7224 | 14.66 | 0.4085 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| Roche Holding AG | 58.79bn | 10.62bn | 219.17bn | 103.61k | 20.29 | 7.39 | 14.75 | 3.73 | 13.23 | 13.23 | 73.21 | 36.32 | 0.6526 | 1.88 | 5.05 | 567,395.40 | 12.76 | 16.12 | 19.22 | 25.24 | 73.71 | 71.48 | 19.55 | 22.98 | 0.9656 | 17.08 | 0.5116 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | -1.13 | 1.99 |
| Merck & Co Inc | 52.87bn | 11.62bn | 254.49bn | 72.00k | 22.01 | 6.90 | 16.85 | 4.81 | 5.39 | 5.39 | 24.66 | 17.19 | 0.5756 | 2.44 | 5.51 | 867,763.90 | 12.67 | 7.70 | 16.42 | 10.29 | 75.79 | 72.26 | 22.01 | 15.03 | 1.22 | 23.69 | 0.464 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 46.54bn | 4.48bn | 288.40bn | 50.00k | 64.55 | 50.27 | 24.56 | 6.20 | 2.99 | 2.99 | 31.03 | 3.84 | 0.3967 | 4.43 | 4.74 | 1,100,000.00 | 3.86 | 6.55 | 5.27 | 8.40 | 66.65 | 69.74 | 9.73 | 16.46 | 0.7061 | 8.92 | 0.9119 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
Data as of Sep 19 2024. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF
17.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Sep 2024 | 76.10m | 3.48% |
| UBS Asset Management Switzerland AGas of 05 Mar 2024 | 68.39m | 3.12% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 55.32m | 2.53% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 37.73m | 1.72% |
| Wellington Management Co. LLPas of 06 Sep 2024 | 33.83m | 1.55% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Jul 2024 | 28.35m | 1.29% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Jul 2024 | 27.93m | 1.28% |
| Geode Capital Management LLCas of 12 Sep 2024 | 20.84m | 0.95% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 18.82m | 0.86% |
| Artisan Partners LPas of 30 Jun 2024 | 18.37m | 0.84% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
